Testing Behavioral Cough Suppression Therapy with and without Inhaled Treatment for Adults with Refractory Chronic Cough

What this Trial Is About

Researchers are evaluating new approaches to help adults with refractory chronic cough RCC, a persistent cough that does not improve with typical treatments. This phase 2 randomized controlled trial investigates behavioral cough suppression BCS therapy combined with either an active inhaled natural substance or an inactive inhaled substance. The study also includes a no-treatment control group to compare effects on cough sensitivity, cough suppression ability, brain response to the urge to cough, and quality of life. Participants are assigned to one of two treatment groups receiving 12 sessions of BCS therapy twice a week, combined with either the active inhaled substance or an inactive inhaled substance. The control group undergoes baseline testing, cough monitoring, and an fMRI brain scan but does not receive treatment during the study. The active inhaled substance is believed to reduce sensory nerve sensitivity and may enhance BCS therapy effects. During the study, participants attend up to 14 clinic visits and two online visits for evaluations including cough sensory threshold testing, brain imaging with fMRI, and ambulatory cough frequency monitoring using a smartwatch. Patient-reported measures of cough impact, voice, sleep, and overall health are collected. The study lasts up to 19 weeks, with outcomes focused on cough sensitivity, suppression ability, brain activity, and quality of life improvements.

Mechanisms of Change in Behavioral Cough Suppression Therapy for Refractory Chronic Cough